Introduction
============

Full cardiac regeneration is well-established in lower vertebrates including amphibians and the teleost fish; in the zebrafish heart, responsive reactivation of resident cardiomyocyte proliferation can occur following severe myocardial injury, such as apex resection, with almost total reconstitution of viable tissue over a transient scar ([@B58]; [@B51]; [@B120]; [@B38]). On the contrary, the adult mammalian heart cannot withstand critical damage, as endowed with poor wound healing response when facing prolonged ischemia. Indeed, the heart responds to an ischemic injury -- such as the occlusion of a coronary artery causing the death of a consistent amount of cardiomyocytes -- by promptly triggering an inflammatory response with activation of myofibroblasts, which rapidly lay down a collagen-enriched scar tissue to compensate the cardiomyocyte loss. Such scar sustains mechanical strength and prevents ventricular rupture thereby avoiding sudden death. Despite this mechanism represents an emergency plan, it has detrimental consequences in the long term, including LV maladaptive remodeling with disruption of cardiac function by ventricular dilatation, scar thinning, and interstitial fibrosis, overall leading to HF ([@B83]; [@B47]). Therefore, the emergency wound healing program can turn into defective repair, which is worsened by absence of efficient myocardial renewal and *de novo* cardiomyocyte restitution.

Restoration of both cardiac structure and function following injury, disease or aging represents the *holy grail* of modern medicine, yet current therapies can only delay progression of HF. In recent years, several preclinical and clinical efforts have focused on stem cell-based therapies, including different cell sources (i.e., BM- and adipose derived-MSC; fetal and perinatal progenitors, etc.) on the assumption that cells transplanted into the heart could give rise to new viable and functional cardiomyocytes and cardiovascular components via direct trans-differentiation. Despite initial high expectations, multiple independent lines of investigation have demonstrated that injected stem cells showed very low engraftment potential, poor survival and in most cases almost complete failure to acquire a mature cardiomyocyte phenotype, yet they contributed to improve cardiac function, mostly via local release of paracrine trophic factors. Indeed, accumulating evidence indicates that stem cells can prime the injured heart via paracrine effects, rather than undergoing *de novo* differentiation, as confirmed by the administration of their conditioned medium that contains all the secreted factors and showed equivalent beneficial results ([@B36]). Thus, stem cell-derived paracrine modulation of cardiac tissue has recently emerged as a promising strategy for enhancing cardiac repair up to regeneration, with growing interest toward the functional profiling of the stem cell "*secretome*," as the whole of growth factors, chemo-attractant molecules and EV produced by paracrine secretion.

In such scenario, much attention has been recently raised toward the strategic role of stem cell-EV as immunologically inert vehicles of regenerative activity and exerting pivotal function in cell-to-cell communication ([@B9];[@B45]). EV are a heterogeneous population of membrane-bound vesicles, including nano-sized exosomes (Ex) and micro-scaled shedding MV ([@B67]; [@B94]). They contain proteins, bioactive lipids, mRNAs, and miRNAs molecules with relevant paracrine potential ([@B9]; [@B45]). Notably, within the EV population, growing interest has been specifically dedicated to the exosome fraction; Ex represent a specific subpopulation of very small EV (ranging in size from 30 up to 150 nm), which are products of the endo-lysosomal pathway and have been described to be functional mediators of regenerative modulatory factors ([@B32]; [@B86]). As such, EV and Ex have been increasingly analyzed in preclinical research, including the field of cancer and cardiac disease ([@B10]).

When addressing cardiac regeneration, two important aspects must be considered as well. First, recent independent studies have revealed that the heart does retain an endogenous regeneration capability, although very limited. Part of this potential is based on CPC activation. CPC are resident cells with stem/progenitor features mainly involved in cardiogenesis during embryonic development and participating in cardiac homeostasis and repair to some extent during adulthood. CPC represent a very heterogenous cell population as described so far, with putative tissue-specific cardiovascular and cardiomyogenic potential and significant paracrine activity, overall supporting cardiac function following injury ([@B18]; [@B67]). Their discovery has overturned the view of the heart as a non-regenerative organ; however, endogenous repair by CPC remains inefficient when facing severe pathological situations, unless they are activated by proper stimulation ([@B18]; [@B53]). They represent a very appealing endogenous therapeutic target to sustain heart regeneration from within the cardiac tissue, therefore comprehensive characterization of CPC-EV and their biological activity has been lately gaining growing attention.

Likewise, the long-held view that mammalian cardiomyocytes are quiescent has been recently dismissed, although the number of mitotic cardiomyocytes drops precipitously within the first week of life. Thereafter, cardiomyocyte renewal rate remains at 0.5--1% per year in adult humans ([@B91]). Despite being clearly insufficient to offset the loss of billion cardiomyocytes following myocardial infarct, a key question is whether this rate of proliferation can be therapeutically enhanced. Notably, it has been shown that in the neonatal mouse heart full regeneration following injury can be underpinned by active proliferation of existing mononuclear cardiomyocytes; unfortunately, this mechanism is transient, being lost after the first week of birth (P7), with transition from complete regeneration to scarring/fibrosis ([@B85]).

Thus, the current cardiac regenerative dogma is based on synergistically optimizing cardiac repair, while also efficiently triggering both endogenous CPC reactivation and resident cardiomyocyte renewal, via paracrine effects. In this scenario, extensive comprehension of EV-mediated intercellular communication might offer meaningful insights for a future working strategy in translational medicine. In this review, we will critically examine the more relevant recent findings related to stem cell-EV biology for cardiac repair and regeneration, while also discussing the paracrine contribution of endogenous CPC and the emerging role of resident cardiomyocyte and the surrounding cardiac stromal cell secretory potential in modulating the tissue microenvironment via EV/Ex interaction.

Stem Cell-EV for Future Cardiac Paracrine Therapy
=================================================

Stem Cell Biology 2.0: From the Genome to the Secretome
-------------------------------------------------------

Within the (stem) cell-based therapy scenario, adult MSC have been the most investigated cell type in preclinical and clinical studies of cardiac repair, in either autologous as well as allogeneic setting. Despite their poor differentiating and engrafting potential, MSC are being considered a promising therapeutic source due to their remarkable cardioprotective, pro-angiogenic and anti-inflammatory paracrine potential. Indeed, in 2006 Gnecchi et al. published a pivotal study demonstrating that Akt-overexpressing MSC produced a cardioactive secretome by conditioning their culture medium, which exerted remarkable beneficial cardioprotective effect when administered to a preclinical rodent model of acute MI ([@B36]). Since then, many independent studies confirmed the favorable paracrine effect on injured myocardium of different MSC sources. Transplanted MSC have been shown to instruct the host cardiac tissue by creating a responsive microenvironment, which is regulated by local concentration of secreted paracrine factors ([@B43]); hence, *in situ* modulation of host cellular responses is unlikely to be mediated by a single or by few factors, but rather by a more complex and synergistic combination of several paracrine agents, such as those conveyed by MSC-secreted EV. Indeed, stem cell-EV cargo can include a mixture of bio-active lipids, proteins and genetic information and has been increasingly scrutinized as therapeutic agent to enhance tissue repair ([@B55]; [@B21]).

Shedding New Light on Stem Cell-EV
----------------------------------

The shift in perspective from the stem cell genome to their secretome, with specific focus on the secreted EV, is transforming the idea of therapeutic application of stem cells in regenerative medicine. Indeed, by replacing cell transplantation with administration of secreted EV, many concerns and limits related to safety and feasibility could be mitigated. Exploiting stem cell-mediated effects via cell-free delivery of paracrine factors may result in a more feasible and clinically translational therapy. Mounting evidences support the working hypothesis of stem cell-EV as promising tool for therapeutic enhancement of cardiac repair mechanisms; several independent studies have reported that intra-myocardial injection of adult MSC-EV in rodent acute MI and I/R models markedly enhanced neovascularization, preserved cardiac function, reduced infarct size and counteracted pathological remodeling ([@B13]; [@B101]; [@B63]; [@B8]). Importantly some evidence suggests this may occur in a dose dependent fashion, as shown by [@B4]. When injecting either 1, 4, or 16 μg/kg of exosomes intravenously in a mouse model of I/R, only the latter two were shown to have cardioprotective potential; this was further confirmed by using a 0.4 μg/ml MSC-Ex buffer in an *ex vivo* I/R injury setting ([@B4]).

Therefore, in recent years growing interest has been addressed to the comprehensive characterization of the cardio-active paracrine profile of stem cell-secreted EV, in order to define an *advanced therapeutic medicinal product* (ATMP) for future cardiac regenerative medicine ([@B82]; [@B94]). Consequently, much attention has been focused on the mechanisms of action dictated by their functional cargo. Despite being very small entities, stem cell-EV (and Ex in particular) represent relatively complex biological conveyors of inter-cellular communication via soluble factors as well as direct horizontal transfer of RNA molecules, mostly represented by miRNAs, as extensively reviewed in [@B42]; [@B56], [@B14], and [@B52].

Indeed, an increasing number of investigations have been suggesting that stem cell-EV can mediate cardiac repair by delivering miRNA content to recipient cells within the heart, thus remarkably reprogramming target cell genetic information. [@B88] were the first to report that human circulating CD34+ hematopoietic precursors release EV endowed with pro-angiogenic miR-130a and miR-126-3p. These EV had relevant potential in inducing neovascularization within the ischemic mouse tissue, as acting on VEGF-, ANG1-, ANG2-, and MMP9- signaling pathways ([@B88]; [@B75]; [@B71]). Similarly, EV from human UC MSC have shown to contained various miRNAs crucial for cardiac and angiogenic cell differentiation of target cells, such as miR-199a-3p, miR-199a-5p, miR-23a-3p, miR-24a, miR-132-3p, miR-21-5p ([@B15]). Murine MSC have also been described to influence cardiac repair following MI in mice by miR-22 transfer via EV delivery, resulting in cardiomyocyte survival and inhibition of the profibrotic marker MeCP2 expression ([@B30]). Furthermore, the direct effect of EV/Ex cargo on cardio-protection was shown in a recent study by [@B65] where an important contribution of miR21a-5p, present in MSC-Ex, was recognized both *in vitro* and *in vivo*. Importantly, by using Ex isolated from miR21a-knockout cells or by using miRNA mimics, they were able to conclude that the delivery of miRNA21a-5p into cardiomyocytes via exosomes and the downregulation of its target is at least partly responsible for apoptosis reduction *in vitro* and *in vivo*, with a smaller infarct size after I/R injury ([@B65]). Besides MSC, mouse embryonic stem cell (ESC)-EV, including Ex, significantly contributed to improve neovascularization, cardiomyocyte survival, and to limit fibrosis post infarction possibly acting via the miR-290-295 cluster ([@B50]). Despite the lack of a general consensus on the most cardio-active miRNA molecular signature within stem cell-EV/Ex, cumulative evidences, reinforced by comprehensive RNA sequencing, indicate the superior therapeutic effect of EV/Ex over MSC alone is due to their specific miRNA enrichment ([@B92]). Likewise, a recent study from our group indicated that human amniotic fluid stem cell-EV (hAFS-EV) are specifically enriched with miRNAs over proteins or other soluble factors; notably direct trafficking of miR-210 and miR-199a-3p from hAFS-EV to responder cells were suggested to drive pro-survival and proliferative effects in recipient human dermal fibroblast and murine myoblasts, which showed significant increase of such putative molecular candidates ([@B5]). This may lay the foundations for further studies to pinpoint specific signaling pathway/molecular targets with relevant therapeutic application for cardiac repair and regeneration; indeed, these miRNAs have been described to exert remarkable effects on the myocardium *in vivo*, as potent drivers of local angiogenesis and cardiomyocyte renewal ([@B29]; [@B3]). As well, to instruct the cardiac tissue to enhance repair and counteract detrimental remodeling following injury, it is crucial to act within the very acute response phase; considering their prompt effect, timely modulation of specific signaling pathways by EV-mediated paracrine action may offer an interesting working strategy.

Nevertheless, additional functional mechanisms have been reported to elucidate stem cell-EV therapeutic effects. For example, Notch-pathway has been proposed as molecular candidate of paracrine intercellular communication, since Jagged 1-endowed MSC-EV induced robust and specific angiogenic response both *in vitro* and *ex vivo* by Matrigel plug assay ([@B37]). As well, human ESC-derived MSC were shown to release Ex restoring the myocardium ATP production while decreasing oxidative stress via functional replenishment of glycolytic enzymes from their cargo into the injured myocardium in a preclinical mouse model of I/R injury ([@B4]; [@B57]).

Critical Aspects for Future Cardiac Paracrine Therapy
-----------------------------------------------------

In the last few years a variety of stem cells have been scrutinized for cardiac repair, including peripheral blood-derived progenitor cells, BM- and adipose-derived MSC, fetal and perinatal stem and progenitor cells, embryonic and iPSC (as extensively reviewed in [@B1]). Given the promising cardioprotective and pro-angiogenic potential of stem cell-EV/Ex, many efforts have recently been focused on identifying the ideal cell source for scaling up the production of EV and Ex as advanced medicinal product for ischemic-related diseases.

Cardiovascular disease patients need prompt therapeutic intervention and it would be ideal to have access to regenerative "off-the-shelf" products for simple administration; hence, stem cells might be used as a "drug store" to produce a highly efficient EV/Ex formulation to provide enhancement of cardiac repair (Figure [1](#F1){ref-type="fig"}). In this scenario, isolation feasibility and elevated self-renewal represents key aspects of the optimal stem cell source to be exploited for future paracrine therapy. Human adult progenitor cells, including MSC, can be isolated from a variety of post-natal tissues and obtained from discarded samples as clinical waste or leftover material during ordinary surgical or screening procedures (blood sampling, liposuction, BM transplantation, etc.). However, they can be affected by low yield and limited self-renewal potential, as they are often influenced by donor age ([@B109]). On the contrary, iPSC may overcome classical drawbacks of adult MSC by offering, in principle, unlimited production of stem and progenitor cells *in vitro*. Indeed, when comparing cardiac reparative effects of murine iPSC against their secreted EV, the latter showed superior paracrine potential in a preclinical model of I/R injury in mouse, thus representing an appealing therapeutic option by offering the benefits of iPSC therapy, but without the risk of tumorigenicity ([@B2]). Yet, iPSC technology can be challenging, costly and time consuming. The more recent characterization of fetal (with non-embryonic origin) and perinatal progenitor cells, have broadened the options. Fetal stem cells isolated either from AF ([@B24]) or villi ([@B84]) as easily collected from leftover sample obtained during routine prenatal screening; perinatal stem cells can be isolated at birth from discarded extra-embryonic annexes, such as UC, including the WJ ([@B112]; [@B100]), and placenta membranes ([@B68]), thus representing an easily accessible source progenitors available in large amount and free from any ethical concern. Fetal and perinatal stem cells can offer specific advantages over adult MSC, since they are endowed with outstanding self-renewal and possibly higher paracrine potential than the adult ones, being developmentally more immature. Indeed, human UC-MSC-EV systemically injected into a preclinical rat model of MI sustained cardiac systolic function after 4 weeks, while offsetting fibrosis and cells apoptosis ([@B121]). Specific interest has also been recently dedicated to the paracrine potential of human amniotic fluid-derived stem cell-EV, as described by few independent studies mediating therapeutic pro-survival, angiogenic, and anti-inflammatory effects ([@B5]; [@B72]; [@B90]; [@B12]).

![Schematic representation of the most relevant effects of extracellular vesicle-mediated intercellular communication within the injured myocardium as providing: **(A)** cardio-protection and cardiac repair by exogenous stem cell-EV/Ex; **(B)** paracrine modulation of the cardiac microenvironment by EV/Ex derived from CPC either activated *in situ* (i) or previously isolated and expanded *in vitro* (ii); and **(C)** fine tuning of adult resident cardiomyocyte and cardiac stromal cell behavior by their mutual EV/Ex modulatory exchange during adaptive response to stress. ATMP, advanced therapy medicinal product.](fphys-09-01497-g001){#F1}

Stromal cell function and secretory potential can be critically determined by the microenvironment scenario. Notably, fine tuning of the microenvironment *in vitro* can significantly and quantitatively influence the cell secretome ([@B59]). Therefore, *in vitro* cell-preconditioning can be adjusted in order to select the ideal cell culture conditions to prime stem cell-EV with optimal cardioprotective and pro-angiogenic potential for therapeutic relevance. For instance, short term hypoxic stimulation has been increasingly used to enrich MSC-EV and Ex with trophic paracrine factors. Delivery of these vesicles resulted in promotion of neovascularization and cardiac repair in preclinical rodent models of MI. The putative mechanisms of action have been reported to involve increased expression of nSMase2, which is critical for exosome biogenesis and EV-mediated transfer of miR-210 ([@B13]; [@B37]; [@B124]). Likewise, transgenic overexpression of specific cardio-active factors within stem cells has been employed to enhance the healing capacity of their secreted EV; overexpression of HIF-1α in human dental pulp-MSC led to secretion of enhanced Jagged 1-loaded exosomes that triggered the angiogenic differentiation of endothelial cells ([@B37]). Moreover, [@B60] previously showed that rat (bone marrow) BM-MSC genetically modified to significantly increase GATA-4 expression, are endowed with noteworthy paracrine pro-survival and angiogenic potential in the ischemic environment. They then exploited the same working strategy to boost the cardioprotective paracrine effect of MSC-Ex in a preclinical rodent model of I/R injury; exosomal reprogramming of resident cardiomyocytes via the delivery of miR-19a targeting PTEN and BIM protein expression resulted in sustained activation of Akt and ERK signaling pathway, with significant recovery of cardiac function and decreased infarct size ([@B117]).

Stem cell-EV are being increasingly considered as biological enhancers of heart repair mechanisms ([@B67]), yet little is known about their cardiac regenerative potential to trigger functional activation of endogenous CPC and responsive resident cardiomyocyte proliferation. Currently only a few studies have provided evidences of such critical effects. Mouse ESC-Ex have been demonstrated to prompt rodent resident c-KIT^+^ CPC survival, proliferation, and cardiac commitment several weeks after *in vivo* administration, with restitution of *de novo* cardiomyocytes in the ischemic heart, possibly via specific miR-294 transfer ([@B50]). Similarly, human iPSC-secreted shedding MV exerted *in vitro* proliferative and protective effects on human cardiac MSC possibly via direct transfer of miR-92b and elicited their cardiac and endothelial differentiation potential ([@B16]). Moreover, rat BM-MSC-Ex showed to prime c-KIT^+^ rat neonatal CPC by reprogramming their miRNA landscape, thus targeting a broad range of biological functions, from positive regulation of cell cycle, up to cell differentiation and response to hypoxia; such MSC-Ex preconditioning strategy also boosted CPC angiogenic ability and increased their *in vivo* functional potency after transplantation into the rat ischemic myocardium ([@B119]). While such data is surely encouraging and very promising, further comprehensive studies are required to specifically assess stem cell-EV potential to sustain functional restoration of myocardial renewal via cardiomyocyte proliferation as well.

While standard cell therapy has been almost completely dismissed, high expectations have now been put into the therapeutic efficacy of stem cell-EV as paracrine facilitators of cardiac repair and regeneration. Indeed, they may represent an appealing alternative cell-free curative modality that could be clinically and translationally effective, safer, and cheaper. However, such a novel approach is still in its infancy as it requires extensive testing to validate EV safety and functional efficacy in the long term.

A Closer Look: Endogenous Cardiac Progenitor Cell-EV for Repair and Regeneration
================================================================================

Mending Broken Hearts From Within: The Biological Relevance of Cardiac Progenitor Cells
---------------------------------------------------------------------------------------

Cardiac progenitor cell represent a heterogenous population of cells scattered throughout the cardiac tissue, including atria, ventricles, and the epicardium ([@B18]). They have been described expressing early cardiac development markers, thereby suggesting promising cardiovascular and cardiomyogenic potential which makes them particularly interesting as a therapeutic target for cardiac regeneration.

The first functional characterization of CPC came from a study by [@B11], describing a population of resident progenitor cells found throughout the ventricular and atrial myocardium expressing markers that were up to that point associated with hematopoietic progenitor cells, including Stem cell antigen-1 (Sca-1) and the tyrosine kinase receptor c-KIT. Upon isolation, c-KIT^+^, Lin-, CD45- CPC were shown to differentiate into cardiac cell types and to contribute to repair of the injured myocardium when transplanted into a preclinical rat model of MI ([@B62]) by significantly decreasing scarring and fibrosis, and possibly by differentiating into cardiac cells. In the following years several other studies followed and focussed on putative different sub-populations of mammalian CPC ([@B33]). These were mainly based on the expression of well-recognized stem cells markers (i.e., c-KIT or Sca-1), by specific isolation and *in vitro* culture protocols, or by their developmental origin, as extensively reviewed in [@B18].

Within the human CPC scenario, two individual progenitor populations have been broadly investigated are the human c-KIT^+^ CPC and the so-called CS or CDC. Since these cells can be easily obtained from cardiac specimens obtained as clinical waste during routine cardiac surgery, their clinical translation was readily pursued. The promising results of c-KIT^+^ CPC transplantation in improving post-infarction left ventricular (LV) dysfunction in preclinical animal models, resulted in the SCIPIO-*Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy* phase 1 clinical trial^[1](#fn01){ref-type="fn"}^. Despite initial reports suggesting that intracoronary infusion of autologous c-KIT^+^ CPC improved LV systolic function and reduced infarct size in patients with HF after MI ([@B17]; [@B23]) recently concern has been expressed over the integrity of previously published data ([@B102]). CS, a heterogeneous population of cells able to spontaneously generate three-dimensional structures, have been described by [@B74] to have stem-like, cardiovascular and cardiomyogenic properties ([@B96]) as well as regenerative influence on the damaged cardiac tissue ([@B48]). Likewise, their promising profile led in 2009 to the CADUCEUS-*CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction* clinical trial to test dose escalation safety and efficacy of intracoronary delivery in patients with ischemic LV dysfunction and MI. While no difference in LV ejection fraction was reported at 6 months follow-up, CPC-treated patients showed reduction in scar mass and improved regional contractility ([@B69]).

Another human derived population that has been described, but has not yet been pursued for clinical application, is represented by Sca-1^+^ CPC. These cells have been shown to differentiate into beating cardiomyocytes and endothelial structures *in vitro* when stimulated with TGFβ or VEGF, respectively ([@B39]). The transplantation of undifferentiated Sca-1^+^ CPC into the MI mouse heart resulted in enhanced cardiac function and expression of human cardiomyocyte markers at 12 weeks follow-up ([@B98]). However, in short-term follow-up, the positive effect on cardiac function was observed in absence of differentiation ([@B27]), suggesting a paracrine effect of the transplanted cells.

More recently, a population of CPC residing within the epicardium -- the outer layer of the heart -- has gained growing attention as a promising target for enhancing cardiac repair and regeneration ([@B76]; [@B97]). During embryonic development there is a clear contribution of epicardial-derived cells (EPDC) to cardio-genesis. EPDC contribute to the smooth muscle component of the coronary vasculature, to interstitial fibroblasts and potentially to ventricular cardiomyocytes, although the latter is still under debate. Moreover, embryonic EPDC contribute soluble factors that stimulate the growth of the myocardium. In the adult heart, the epicardium is a quiescent layer, only to become activated after MI, as shown by an upregulation of embryonic markers, proliferation and migration ([@B123]). Given the developmental ability of EPDC, and their partial activation post-injury, the epicardium and its derivatives are an intriguing endogenous cell type to pursue with respect to cardiac repair. Interestingly, [@B95] showed that priming the epicardial response by systemic injection of the small cardio-active peptide thymosin β4 prior to infarction resulted in an increased activation and enhanced cardiac function, potentially accompanied by differentiation of EPDC into cardiomyocytes. EPDC can be isolated and cultured from different human cardiac samples including adult atrium samples and fetal cardiac specimens ([@B108]; [@B76]). When injected into to the infarcted mouse heart, EPDC where shown to positively affect cardiac function and stimulate local angiogenesis up to 6 weeks post-MI ([@B114]), but in the absence of the transplanted cells' survival, thereby arguing for a paracrine contribution of EPDC to cardiac repair. This was further confirmed by studies where the conditioned medium of cultured mouse EPDC was shown to stimulate angiogenesis, and its injection into the heart resulted in reduced infarct size and enhanced cardiac function and local angiogenesis ([@B122]).

CPC Paracrine Potential via EV-Based Communication
--------------------------------------------------

Recent studies have emphasized that *ex vivo* cultured CPC show low engraftment and very limited differentiation potential within the injured myocardium ([@B114]; [@B98]; [@B31]), while positive effects on cardiac function could have been recorded ([@B125]). Indeed, a very recent study based on an optimized genetic lineage trace has questioned the cardiomyogenic differentiation potential of the endogenous so-called cardiac "stem" cells or CSC, as showing that, opposite to what happens during embryonic cardiogenesis, in the adult heart *de novo* cardiomyocytes do not derive by putative resident cardiac stem cells ([@B61]).

Thus, given that the biological profile of CPC is still quite controversial in terms of specific cardiovascular and cardiomyocyte commitment, there is now a general consensus on their substantial paracrine activity to exert cardioprotective effects, while increasing cardiac function. Hence, attention has moved to the paracrine profile of these cells with a particular interest in the functional characterization of CPC-EV, including Ex.

Indeed, several studies have highlighted the remarkable role of CPC-EV in enhancing cardiac repair mechanisms and promptly modulating acute inflammation, while sustaining long-term cardiac function. [@B45] recently showed that the EV secreted by CDC recapitulated the regenerative effects of the whole CDC secretome, including their pro-survival, proliferative and angiogenic effects on cardiac cells, both *in vitro* and *in vivo*. Similar beneficial results were also validated by an independent study from [@B9] in which the cardioprotective effect of EV obtained from CPC derived from atrial appendage explants was tested against those derived from human dermal fibroblast. Indeed, human CPC-EV were shown to be the most cardio-active component of the progenitor cell paracrine secretome, as rodent infarcted hearts injected with EV from CPC, but not from control fibroblasts, prevented cardiomyocyte from apoptosis, enhanced neovascularization, and improved LV ejection fraction ([@B9]). Moreover, [@B106] confirmed the therapeutic potential of cardiosphere-derived-EV in reprogramming fibroblast behavior and secretome, by making them less pro-fibrotic, more angiogenic and cardioprotective. Lately, human CDC-EV therapeutic feasibility has also been validated in a large animal preclinical model of MI in pigs, by intracoronary (IC) or open-chest intramyocardial (IM) delivery, after reperfusion in acute or chronic settings ([@B34]; [@B79]). Local Ex delivery proved to be effective in decreasing fibrosis and adverse remodeling, while improving cardiac function after a single dose or follow up treatments in the long term; notably, the more clinically suitable IC administration did not produce equivalent beneficial results, suggesting that delivery route and timing are critical aspects for future cardiac paracrine therapy ([@B34]).

CDC-Ex have been shown to horizontally transfer into target cells, resulting in critical decrease of scar mass and significant improvement of global cardiac function following MI. Notably, miR-146a was identified as particularly enriched within CDC-Ex and playing an important role in mediating some of the nanovesicle trophic effects, such as inhibiting pathological remodeling and increasing viable myocardium mass in a murine preclinical model of MI ([@B45]). Yet, selective administration of miR-146a mimic reproduced only some -not all- the benefits obtained via CDC-Ex, suggesting that, while playing a significant role as part of their cargo, it cannot be considered as the individual molecular candidate to confer comprehensive therapeutic benefit to the injured heart. These results suggest a more cautious attitude toward the translation of EV/Ex biology into the clinical scenario and functional identification of discrete factors within their cargo as future pharmacological molecules with cardio-regenerative effects cannot be considered a straightforward approach yet.

Human CPC-EV have been also described as carrying cardio-active miRNAs including miR-210, miR-132, and miR-146a-3p, which affect the expression of Ephrin A3 and PTP1b in the responder cells, and subsequently lead to inhibition of cardiomyocyte apoptosis and enhancement of angiogenic differentiation by endothelial cells ([@B9]). Another relevant therapeutic miRNA enriched in CDC-EV is miRNA-181b ([@B25]) as described to convey remarkable immunomodulatory effects, by decreasing CD68^+^ macrophages infiltrating in the heart after MI. Yet, miRNAs are not the only "usual suspects" driving EV- and Ex-derived regenerative effects. Recently, another class of non-coding RNA, the Y RNAs, has been reported to be plentiful in CPC-EV. [@B19] showed that a Y RNA fragment highly enriched in human CDC-EV can be actively transferred into macrophages, endowing them with cardioprotective potential and mediating strong anti-inflammatory and pro-survival effects in rodent hearts undergoing I/R injury ([@B19]).

CPC-EV can directly deliver proteins to recipient cells as well. For instance, the pro-angiogenic effects of human Sca-1^+^ CPC-EV on endothelial cells *in vitro* and *in vivo* was shown to be regulated through high levels of EMMPRIN within these vesicles ([@B110]). Notably, when exosome EMMPRIN was blocked via neutralizing antibodies, authors detected a significant reduction in EV-mediated angiogenic effects *in vitro*. Such result was further enhanced by shRNA-induced knock-down as EMMPRIN-deprived EV failed to stimulate network formation in a Matrigel tubule assay to the same extend as control untreated EV. Since enhancement of local angiogenesis is critical to optimize cardiac repair and improve functional recovery in the long term, this study provides interesting insights about exploiting specific EV molecular strength to drive effective pro-angiogenic responses within the damaged heart, such as vessel growth into the border zone and infarcted area. Similarly, a recent study compared the paracrine potential of human CPC-EV against the ones derived from bone marrow-derived mesenchymal stromal cell (BM-MSC), in an rodent model of MI ([@B8]). Results revealed that the superior cardioprotective role of CPC-EV could be related to a specific mechanism of action in the vesicle release of IGF-1 as mediated by PAPP-A, which was significantly enriched in the EV secreted by CPC over BM-MSC ones ([@B8]). The functional role of PAPP-A as master regulator of CPC-EV potential was further validated by transfecting cells with PAPP-A-specific siRNA; EV from PAPP-A-knockdown CPC did not inhibit cardiomyocyte apoptosis *in vitro*, nor counteracted LV dysfunction after permanent coronary ligation *in vivo* in rodents, hence highlighting the pivotal operative role of such protein on CPC-EV surface. Of interest, this study suggested a mechanism of action driving vesicle cardioprotective capacity other than the traditional view on EV mainly acting via intracellular delivery of their molecular cargo to target cells, hence providing new starting points for future strategies influencing cardiac repair and remodeling.

Several studies have addressed and comprehensively analyzed the paracrine potential of endogenous CPC-EV/Ex in optimizing cardiac repair by exerting beneficial cardio-protective, immunomodulatory, and angiogenic effects. Nevertheless, in order to define whether CPC-EV might represent an ideal future therapeutic candidate over exogenous stem cell-EV, further investigation should be provided on their cardio-active potential to restore and efficiently sustain myocardial renewal following injury. Indeed, so far very few studies have addressed such aspect, which is one of the most challenging for cardiac regenerative medicine. To the best of our knowledge, currently available data on CPC-EV potential to trigger cardiomyocyte proliferation is limited to *in vitro* analyses ([@B9]; [@B45]).

Moreover, since CPC offer the unique advantage to mediate endogenous cardiac regeneration from within the cardiac tissue, a consensus on the most effective strategy to unlock their paracrine potential *in situ* is strongly needed. Indeed, adult CPC are usually quiescent or dormant and not efficiently responsive when facing injury or disease. Ideally, since they represent endogenous progenitors residing within the myocardial tissue, it would be advantageous to trigger their paracrine potential via EV release *in situ* by appropriate stimulation. Otherwise, CPC can be easily isolated from clinical waste specimen during routine cardiac surgery, *ex vivo* expanded and preconditioned with specific stimuli as for exogenous stem cells (Figure [1](#F1){ref-type="fig"}); however, being less immature and tissue-specific committed progenitors, such high level of processing can influence their behavior, secretome composition and yield.

Resident Cardiovascular Cell Inter-Communication: the Cardiomyocyte-Fibroblast EV Axis
======================================================================================

A whole body of experimental research indicates that cardiomyocytes and cardiac stromal cells, especially fibroblasts (Fib), influence one another via cell-to-cell contact and, to a larger extent, paracrine mediators ([@B44]; Figure [1](#F1){ref-type="fig"}).

Several authors showed that co-culturing cardiac stromal cells and cardiomyocytes or incubating either cell population with the culture medium conditioned by the other one, results in significant structural and functional modifications. In most cases, it was demonstrated that cardiac Fib affect aspects of cardiomyocyte biology, such as hypertrophy ([@B20]), electrical activity ([@B80]), contractility ([@B54]), and viability ([@B93]). Nonetheless, it was also found that other stromal cell types, such as endothelial cells, modulate cardiomyocytes in culture systems ([@B113]) as well as that cardiomyocytes may in turn regulate Fib and other non-cardiomyocyte populations ([@B20]; [@B35]).

A second line of evidence consists of experiments with animal models, in which elimination of single cardiac Fib-secreted factors by genetic manipulation led to pathological ventricular remodeling in response to pressure overload ([@B81]; [@B89]; [@B99]). Overall, these studies have confirmed that the interaction between cardiomyocytes and non-cardiomyocytes described *in vitro* does occur also *in vivo*, and that any perturbation of this crosstalk invariably causes myocardial disease and HF. Interestingly, the same mediators may transmit signals from cardiomyocytes to stromal cells and vice versa. For instance, transgenic mice overexpressing the Notch ligand, Jagged1, on the surface of cardiomyocytes (which activates Notch signaling in contiguous cardiomyocytes and non-cardiomyocytes) display enhanced proliferation of CPC and cardiomyocytes in neonatal life, and reduced cardiomyocyte hypertrophy, blunted cardiac Fib expansion and fibrosis, and increased numbers of Sca-1- and Nkx2.5-positive CPC following pressure overload when adult ([@B78]). On the other hand, genetic or pharmacological inhibition of Notch signaling in cardiac endothelial cells impairs the supply of fatty acids across the endothelium to cardiomyocytes, which thereby switch to maladaptive glucose-dependent energy metabolism; along with uncontrolled angiogenesis, this derangement promotes HF ([@B46]).

Within this scenario of complex intercellular communications, a role for EV has been repeatedly proposed. In a seminal work, [@B104] demonstrated that miR-21 stimulates cardiac Fib survival and activity, up to the point that silencing of miR-21 by a specific antagomir-21 significantly reduced LV fibrosis and dysfunction in mice subjected to pressure overload by transverse aortic constriction. Building on these findings, these and other authors subsequently showed that cardiac Fib secrete Ex enriched for miRNAs and miRNA passenger strands, despite these latter being predicted to be degraded during miRNA biogenesis ([@B6]). In particular, miR-21 passenger strand (miR-21^∗^) is highly expressed in Ex from cardiac Fib, is further increased by angiotensin II, and is implicated in hypertrophy of cardiomyocytes ([@B6]). Consistent with these observations, repression of miR21 by means of antagomir-21 and pharmacological blockade of miR-21^∗^ counteracted transverse aortic constriction- and angiotensin II-initiated LV hypertrophy, respectively ([@B104]; [@B6]). Other investigators subsequently confirmed that Ex are synthetized by cardiac Fib upon exposure to angiotensin II and cause cardiomyocyte hypertrophy in a paracrine manner, and that found that inhibition of Ex release attenuated angiotensin II-elicited cardiac hypertrophy ([@B66]). Remarkably, cardiac Fib Ex were also shown to induce a cell-intrinsic renin-angiotensin system in cardiomyocytes ([@B66]), and angiotensin II-primed cardiomyocytes were reported to induce miR21 signaling in cardiac Fib ([@B64]), substantiating the concept that the crosstalk between cardiomyocytes and stromal cells is bidirectional and at multiple levels.

To add a further layer of complexity to the EV-mediated cell inter-communication within the myocardium, there is evidence that EV with potential paracrine effects are also released by cardiomyocytes, in spite of being these cells usually considered non-secretory. A pioneering study conducted in 2007 demonstrated the ability of cultured adult cardiomyocytes to secrete Ex containing HSP60, which is involved in regulation of cardiomyocytes apoptosis and inflammation and, therefore, may play a primary role in myocardial pathology ([@B105]). Expanding on these findings, it was subsequently observed that Ex secretion by cardiomyocytes is tightly regulated by the microenvironment and by ROS production and that cardiomyocytes-derived Ex have a peculiar protein content pattern, enriched for sarcomere and mitochondrial proteins, which is related to the stimuli driving EV formation ([@B70]). In fact, the effects of Ex from cardiomyocytes was different depending on the oxygen concentration to which cardiomyocytes were exposed: Ex released by cardiomyocytes in hypoxic condition displayed an increased cardioprotective activity compared to normoxic condition, with enhanced angiogenesis. This latter was at least in part due to higher levels of miR-222 and miR-143 ([@B87]). Other molecules highly present in cardiomyocyte EV are mRNAs, with 423 out of the 1520 mRNAs detected being connected in biological networks, in particular regarding energy metabolism ([@B111]).

A major limitation in investigating EV and Ex from cardiomyocytes is that it is not possible to set a human culture, and studies typically rely on various cell types -- the murine cardiomyocyte HL-1 cell line, the rat cardiomyoblast H9c2 cell line, rat primary fetal cardiomyocytes and even adult rat cardiomyocytes ([@B40]; [@B111]; [@B87]), none of which reliably reproduces the main features of human adult cardiomyocytes. To overcome this drawback, the use of cardiomyocytes obtained from iPSC may hold great promises ([@B28]).

Open Questions
==============

Cell-secreted vesicle biology is becoming a rapidly expanding field with dramatic impact on future cardiac regenerative medicine, given the noteworthy role of EV and Ex in driving heart repair and regeneration, while also regulating interaction among resident cardiomyocytes and surrounding stromal cells, as summarized in schematic Figure [1](#F1){ref-type="fig"}. Nonetheless, many critical aspects need further investigation in order to clearly define their clinical translational potential.

Extracellular vesicles represent a very heterogeneous population, being enriched with both Ex and MV. While several independent studies suggest Ex over MV as key mediators of biological modulatory effects ([@B10]; [@B77]), a general consensus on the most functionally cardio-active fraction between the two hasn't been reached yet, since the comprehensive paracrine profile of Ex over MV is still undefined ([@B107]). Indeed, the structural heterogeneity of EV represents a challenge for our understanding of their biological functional role, as currently much remains unspecified regarding the detailed origin, regulatory pathways of secretion and cell targeting mechanisms. Likewise, tumorigenic Ex themselves have been lately described to be further fractioned into distinct subsets: large exosomes (ranging from 90 up to 120 nm), small exosomes (from 60 to 80 nm) and a third class of non-membranous nanoparticles defined as *exomeres* (about 35 nm). This additional sub-classification seems to be recapitulated by distinct proteomic, lipid, and nucleic acid content that influences organ biodistribution and pleiotropic effects related to cell metabolism, proliferation and secretion pathways ([@B118]).

When considering clinical translation feasibility for future therapy, the overall reproducibility of the isolation methods as well as the efficiency of the product must be carefully considered. For example, it has yet to be determined whether endogenous CPC might be a preferential source over exogenous stem cells to harness cardio-active EV/Ex from. While CPC have to be either powerfully reactivated *in situ* with specific stimuli or harvested by invasive procedure and then expanded *in vitro* to exploit their paracrine potential, exogenous MSC can be obtained by a variety of clinical waste samples that may be much easily available. Likewise, iPSC may offer the advantage of being cultured in large quantities from a single isolation, providing a reliable background. Yet, given their ability to produce cardiac cell types, the CPC populations represent an interesting cell source to focus on, and may be especially efficient when cultured under conditions that resemble the injured myocardium (e.g., hypoxia or extracellular matrix composition).

Another relevant aspect influencing EV biology is related to their isolation protocol, from either cell-conditioned culture medium or biological fluids, including blood serum. Many different techniques have been reported and characterized: differential ultracentrifugation, immunoaffinity capture, ultrafiltration, size-exclusion chromatography, polymer-based precipitation up to state-of-the-art microfluidics ([@B103]; [@B22]; [@B73]; [@B100]; [@B49]; [@B41]). Therefore, the ideal method for EV clinical translation and their scale-up standardization as future ATMP still represents a major challenge. Indeed, while most protocols aim at increase efficiency and efficacy of the isolation yield, many of them present relevant concerns about contamination of cell-derived molecules or do not offer reliable EV sub-fractioning into Ex versus MV from cell-conditioned medium as well as biological fluids ([@B7]; [@B94]). Recently, asymmetric flow field-flow fractioning has opened up a new promising scenario for the efficient isolation of distinct EV subpopulations, via highly reproducible, fast, simple, label-free technology ([@B118]).

These methodological issues also represent a current major limitation to the possibility of measuring EV in the bloodstream for diagnosis of cardiac disease. In principle, increased circulating concentrations of EV containing myocardial-specific markers (proteins, lipids, and RNA) may allow the recognition of some cardiac disorders earlier and/or more accurately than by using conventional biomarkers, such as troponins and natriuretic peptides ([@B94]). In fact, seminal work has pinpointed EV content profiles selectively associated with acute coronary syndromes ([@B26]), HF ([@B115]), and chemotherapy-induced cardiomyopathy ([@B116]). Nonetheless, the aforementioned technical aspects should not be overlooked and future prospective studies, designed *ad hoc*, are warranted to confirm the value of EV as biomarkers of cardiovascular disease in the clinical arena.

Extracellular vesicles participate in myocardial cell inter-communication and, in principle, novel therapies for LV hypertrophy and HF may target the cardiomyocyte-cardiac stromal cell paracrine axis or specific mediators that their EV may carry. Moreover, being EV also involved in physiological responses to stress, it will be extremely challenging to tailor innovative therapeutic approaches that inhibit detrimental effects, while preserving EV beneficial function in maintenance of cardiac homeostasis.

As several studies have emphasized the direct effect on EV cargo on their target cells to influence for instance angiogenesis ([@B110]) or cardio-protection ([@B65]), establishing whether the combination of discrete paracrine factors (either distinct soluble factors or nucleic acid information) identified within the vesicle cargo can completely recapitulate EV cardioprotective and/or regenerative effects can offer critical information for future pharmacological applications. As well, the most efficient and less invasive administration protocol for putative EV-based cardiac paracrine therapy has to be characterized yet; indeed, while single administration during angioplasty procedure may be clinically feasible, maintenance of therapeutic levels in the long term might require follow-up treatments which should be delivered to the myocardial tissue as exclusively as possible. Moreover, dose-response effects need to be comprehensively investigated; currently information on this specific aspect is quite limited and general consensus on the most appropriate method to measure the EV dose to be employed has not been reached yet. Indeed, in most studies the dose of EV administered *in vitro* and/or *in vivo* has been indicated by number of EV particles/μl ([@B45]; [@B34]; [@B8]) or by μg of EV total protein ([@B4]; [@B9]; [@B5]), or as the amount of EV obtain by a specific number of producing cells ([@B88]). Likewise, pharmacokinetics and pharmacodynamics of EV-based formulations need to be comprehensively investigated in order to avoid any potential adverse side effects of therapeutic dose, while ensuring efficacy.

Overall, EV biology surely represents a fascinating and promising field to be therapeutically exploited for future cardiac repair and regeneration strategies; yet our understandings of EV basic mechanisms of action within the myocardial tissue, from their biogenesis to cell targeting and specific delivery of the informative content, need to be significantly improved.
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AF

:   amniotic fluid

ANG1

:   angiopoietin 1

ANG2

:   angiopoietin 2

ATMP

:   advanced therapy medicinal product

BM

:   bone marrow
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:   cardiosphere-derived progenitor cells

CPC

:   cardiac progenitor cell

CS

:   cardiospheres

EMMPRIN

:   extracellular matrix metalloproteinase inducer

EPDC

:   epicardium-derived progenitor cells

ERK

:   extracellular signal--regulated kinase

ESC

:   embryonic stem cells

EV

:   extracellular vesicles

Ex

:   exosomes

Fib

:   fibroblasts

HF

:   heart failure

HIF

:   hypoxia inducible factor

HSP60

:   heat shock protein 60

I/R

:   ischemia/reperfusion

IC

:   intra-coronary

IM

:   intra-myocardial

iPSC

:   induced pluripotent stem cells

Lin-

:   lineage-negative

LV

:   left ventricle

MeCP2

:   Methyl-CpG binding protein 2

MI

:   myocardial infarction

miRNA

:   microRNA

MMP9

:   matrix metallopeptidase 9

mRNA

:   messenger RNA

MSC

:   mesenchymal stromal cells

MV

:   microvesicles

nSMase2

:   neutral sphingomyelinase 2

PAPP-A

:   pregnancy-associated plasma protein-A

ROS

:   reactive oxygen species

UC

:   umbilical cord

VEGF

:   vascular endothelial growth factor

WJ

:   Wharton's jelly
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